Advertising in the International Journal of Infertility & Fetal Medicine: A Complete Guide for Medical Brands and Agencies in India

Most pharmaceutical and medtech companies we speak with have a clear idea of which television channels they want to be on, but when it comes to peer-reviewed medical journal advertising in India, the decision-making gets surprisingly vague. That is a missed opportunity, and nowhere is it more visible than with the International Journal of Infertility & Fetal Medicine — a publication that sits squarely in front of the specialist audience that reproductive health brands need to reach, yet remains underutilised as an advertising channel. The infertility treatment India market is projected to grow at a compounding rate that few other therapeutic segments can match, which makes the timing of getting into IJIFM advertising particularly relevant for brands in assisted reproduction, IVF, and fetomaternal medicine right now.

What Is IJIFM and Why Does It Matter for Medical Advertisers in India?

The International Journal of Infertility & Fetal Medicine is a peer-reviewed journal published by Jaypee Brothers Medical Publishers (P) Ltd., one of India's most respected names in health science publishing India, operating out of Ansari Road, Daryaganj, New Delhi – 110 002. The journal was founded under the editorial stewardship of Dr. Kamini A. Rao, a Padma Shri awardee and a foundational figure in reproductive medicine in India; the current Editor-in-Chief is Dr. Geetha Balasarkar, whose academic standing in the field lends the journal its scientific authority. IJIFM carries the print ISSN 22293817 and the online ISSN 22293833, and it is published on a triannual schedule — three issues per year — which concentrates advertiser attention rather than diluting it across monthly editions the way some other journals do.

What makes this journal particularly interesting from a media planning standpoint is its positioning at the intersection of two high-value clinical specialties: reproductive endocrinology and fetomaternal medicine. These are not general practitioners flipping through a magazine in a waiting room; these are subspecialists who make prescribing and procurement decisions worth crores of rupees annually. The journal covers original research, case reports, and clinical reviews across assisted reproduction, embryology, andrology, obstetrics gynaecology, and fetal medicine — which means the readership profile is unusually concentrated for a single publication. At SmartAds, we always tell our clients that concentration of the right audience is worth far more than raw circulation numbers, and IJIFM is a textbook example of that principle in action.

The publisher, Jaypee Brothers Medical Publishers, also operates the Jaypee Journals platform at jaypeejournals.com and the digital library JaypeeDigital at jaypeedigital.com, which extends the journal's reach beyond the print edition into an online environment where digital advertisements can be served to readers accessing full-text articles. The journal is also associated with the International Institute for Training and Research in Reproductive Health (IIRRH), which gives it an institutional credibility that purely commercial publications simply cannot replicate; for a pharmaceutical company or medtech advertiser trying to establish brand credibility among key opinion leaders in reproductive health, that association matters enormously.

Who Are the Readers of IJIFM — and Why Should Your Brand Reach Them?

The gynaecologist readership India that IJIFM commands is not a homogeneous group, and understanding its composition is the first step toward building a compelling case for advertising investment. The core readership consists of reproductive endocrinologists, IVF specialists, embryologists, andrologists, and fetomaternal medicine consultants — professionals who are, by the nature of their practice, high-frequency prescribers and decision-makers for fertility drugs, ART consumables, diagnostic equipment, and surgical instruments. A reproductive endocrinologist audience of this kind is genuinely difficult to reach through mass media channels; they are not heavy television viewers during working hours, and their digital consumption tends to be fragmented across medical databases and clinical apps rather than concentrated on social media platforms where display advertising is conventionally bought.

What a lot of people miss is the secondary readership layer that a journal like IJIFM carries: postgraduate students in obstetrics and gynaecology, research fellows in reproductive medicine, and hospital procurement officers who use journal advertising as a reference point when evaluating new products. We have seen this play out directly in a campaign we ran for a fertility diagnostics company — a client based out of Hyderabad that was launching a new AMH testing kit targeted at IVF centres across South India. They had been spending their budget almost entirely on conference sponsorships, which delivered good face time but limited sustained recall; when we shifted a portion of their budget into IJIFM magazine advertising alongside a coordinated digital campaign, the brand recall among gynaecologists in their target cities improved measurably over two subsequent quarters, with several clinics citing the journal advertisement as the first point of awareness.

The urologist advertiser India angle is also worth mentioning here, because male factor infertility is a growing area of clinical focus, and andrologists who treat male infertility are a meaningful subset of IJIFM's readership. For brands in the andrology space — sperm analysis equipment, male fertility supplements, hormonal therapies — this is one of the very few Indian publications where the readership profile justifies a dedicated insertion rather than a general medical journal buy. On top of that, the journal's association with societies like the Indian Fertility Society and the broader ecosystem of the Federation of Obstetrics and Gynaecological Societies of India (FOGSI) means that content and advertising in IJIFM circulates within professional networks that extend well beyond the direct subscriber base.

What Types of Advertisements Does IJIFM Accept in Print and Digital Formats?

The print advertisement options in IJIFM follow the standard formats established by Jaypee Brothers Medical Publishers across their journal portfolio, which includes full-page colour advertisements, half-page insertions, back cover and inside cover premium positions, and centre-spread placements for brands that want maximum visual impact. Full-page colour is the most commonly booked format among pharmaceutical companies launching new molecules or line extensions in the reproductive medicine space, and it works out to roughly the kind of investment that most specialty pharma marketing managers would allocate to a single conference sponsorship — which, when you think about the sustained three-issue annual reach versus a two-day event, is a comparison that tends to shift budget thinking fairly quickly.

Beyond the standard print advertisement formats, IJIFM also offers digital advertisement placements through the Jaypee Journals online platform and JaypeeDigital, where banner ads and sponsored content units can be placed alongside full-text article access. The digital advertisement opportunity here is particularly interesting because of the journal's open access policy — articles published under the CC-BY-NC open access license are freely accessible to readers without a subscription paywall, which means that digital ad impressions are not gated behind institutional access the way they would be in a subscription-only journal. Frankly speaking, this is a detail that most media planners overlook entirely when evaluating medical journal advertising India options; an open access journal generates significantly more online traffic than a paywalled equivalent, which translates directly into more digital ad exposures per issue cycle.

The commercially sponsored advertisement category in IJIFM also includes insert cards, loose inserts bound into the print edition, and product monograph placements — formats that are particularly popular among medtech companies launching new devices or consumables into the IVF advertising space. We have worked with a medical device manufacturer in the ART space who used a loose insert in IJIFM to distribute a detailed product comparison chart to clinicians; the format allowed for more technical detail than a standard print advertisement, and the feedback from their field sales team was that it generated more informed conversations with specialists than any other piece of promotional material they had used that year. The key, as we have found consistently, is matching the format to the message — a complex clinical positioning argument needs space, and IJIFM's print formats provide that.

How Do You Book an Advertisement in the International Journal of Infertility & Fetal Medicine?

The ad booking medical journal process for IJIFM runs through Jaypee Brothers Medical Publishers directly, and the primary advertising contact is Mr. Sanjeev Kumar, whose email address is sanjeev.kumar@jaypeebrothers.com — this is the correct point of contact for rate card requests, format specifications, and booking confirmations. The process is more straightforward than many first-time advertisers expect; it does not require going through a complex programmatic buying platform or navigating multiple approval layers, which is one of the practical advantages of working with a publisher of Jaypee Brothers' scale and experience in health science publishing India.

The ad material submission deadline for IJIFM follows a standard lead time requirement of four weeks prior to the print date of the relevant issue, which means that for a triannual publication, advertisers effectively have three booking windows per year — and missing the four weeks prior print date deadline for one issue means waiting for the next cycle. This is something we always flag to clients early in the planning process, because the lead time for pharmaceutical advertising is often longer than the four-week submission window alone; regulatory review, medical-legal approval, and artwork finalisation can collectively add another three to six weeks to the timeline, which means the effective planning horizon for a first-time IJIFM advertiser is closer to two to three months before the desired issue date. Purchase order payment advertisement terms with Jaypee Brothers are typically settled in advance of publication, which is standard practice across Indian medical journal advertising.

To be honest, the smoothest campaigns we have managed for clients advertising throughout the year in IJIFM have been the ones where we locked in a multi-issue commitment at the start of the financial year rather than booking issue by issue. Jaypee Brothers, like most Indian medical publishers, is open to annual rate negotiations for multi-issue bookings, and the savings can be meaningful — particularly for brands that want to maintain consistent visibility across all three issues of the publication schedule. At SmartAds, our approach to ad booking in specialty medical journals always starts with a full-year audit of the publication calendar, which allows us to align issue placements with product launch timelines, conference seasons, and clinical awareness months relevant to the therapeutic area.

What Are IJIFM's Advertising Policies and Compliance Requirements?

The journal advertising policy of IJIFM is grounded in the editorial independence principles that Jaypee Brothers Medical Publishers upholds across its journal portfolio, which means that commercially sponsored advertisement content is reviewed to ensure it does not influence the editorial content of the journal in any way. This is not merely a formality; the editorial team maintains a clear separation between advertising decisions and content decisions, and advertisers should not expect — or attempt to negotiate — any form of editorial coverage in exchange for advertising spend. We have seen this backfire when agencies unfamiliar with medical journal norms attempt to bundle advertising with editorial placement requests; it damages the relationship with the publisher and, more importantly, it is simply not how credible peer-reviewed journals operate.

For pharmaceutical advertising specifically, IJIFM requires that all drug advertisements include the generic name prominently alongside the brand name, which aligns with the broader requirement under Indian pharmaceutical advertising regulations that the drug advertisement generic name must be displayed clearly. Advertisements for prescription drugs must also include a summary product characteristics section or a reference to the marketing authorization summary product characteristics document, ensuring that clinician readers have access to prescribing information. Healthcare advertising compliance India in the context of peer-reviewed journals is governed by a combination of CDSCO guidelines, the Indian Medical Council's code of ethics, and the publisher's own advertising standards — and IJIFM takes all three seriously. Any advertisement that makes unsubstantiated clinical claims, uses comparative efficacy data without peer-reviewed citation, or promotes off-label use will be rejected by the editorial team without exception.

The question of what happens to rejected advertisement content is one that comes up regularly in our client conversations, and the answer is straightforward: Jaypee Brothers will communicate the specific grounds for rejection and, in most cases, allow the advertiser to revise and resubmit within the same issue cycle if there is sufficient time before the print date. What are the best practices for creating compliant pharmaceutical ads in IJIFM? From our experience, the most effective approach is to have the advertisement copy reviewed against IJIFM's stated journal advertising policy before finalising artwork — not after. Building the compliance review into the creative development process, rather than treating it as a final gate, saves time and avoids the frustration of late-stage rejections. We routinely provide our pharma clients with a regulatory and ethical checklist aligned to both CDSCO requirements and Jaypee Brothers' publisher standards before any ad material goes to the design team.

How Does IJIFM Compare to Other Indian Infertility and Obstetrics Journals for Advertising?

The Indian obstetrics gynaecology journal landscape offers several options for advertisers in the reproductive health space, and IJIFM occupies a specific and defensible position within that landscape. The Journal of South Asian Federation of Obstetrics and Gynaecology (JSAFOG), published under the FOGSI publication advertising umbrella, has a broader readership that spans general obstetricians and gynaecologists across South Asia, which makes it a better fit for brands with a wider clinical target — but for advertisers specifically focused on infertility, ART, and fetomaternal medicine, that breadth comes at the cost of audience precision. The Indian Journal of Obstetrics and Gynecology Research (IJOGR) similarly covers a wide clinical territory, which is valuable for certain product categories but dilutes the specialist concentration that IJIFM delivers.

The Donald School Journal of Ultrasound in Obstetrics and Gynecology (DSJUOG) is another Jaypee Brothers publication that is worth considering for brands in the diagnostic imaging and fetal medicine space; it has strong international readership and a distinct positioning in ultrasound and prenatal diagnosis, which makes it complementary rather than competitive to IJIFM for advertisers with a fetomaternal medicine focus. What we typically recommend to clients with budgets that can support two journals is a combination of IJIFM for the reproductive endocrinology and IVF advertising audience and DSJUOG for the imaging and prenatal diagnosis audience — the two publications together cover the specialist clinical journey from conception to delivery in a way that no single journal can.

On the question of the Indian Fertility Society journal and other ART journal India publications, the landscape is less developed than the obstetrics and gynaecology space; IJIFM remains the most established peer-reviewed journal with a dedicated infertility and fetal medicine focus that also has a clear advertising infrastructure through Jaypee Brothers. The ISSRF — the Indian Society for the Study of Reproduction and Fertility — publishes its own journal, but its advertising reach and infrastructure are more limited. For medtech advertising India companies entering the Indian fertility market, IJIFM combined with a targeted conference presence at events affiliated with the Indian Fertility Society represents, in our view, the most cost-effective specialist media combination available.

What Is the Publication Schedule and Lead Time for IJIFM Advertisements?

The publication frequency triannual schedule of IJIFM means that the journal publishes three issues per year, which creates a rhythm that is actually quite manageable for advertisers — particularly those in the pharmaceutical and medtech space who are accustomed to the longer planning cycles that regulatory review demands. The three annual issues are typically spaced to cover the beginning, middle, and end of the calendar year, though the precise issue dates should be confirmed with Mr. Sanjeev Kumar at Jaypee Brothers when booking, as publication timelines can shift slightly based on editorial submission volumes. What this triannual cadence means practically is that advertisers who want to advertise throughout the year need to commit to all three issues, which is both a planning discipline and an opportunity — three insertions across twelve months is a frequency level that builds genuine brand recall among a specialist readership that encounters the journal regularly.

The four weeks prior print date deadline for ad material submission is firm, and we have found that the most common source of missed placements is not budget or approval issues but simply artwork that arrives late because the internal review process took longer than anticipated. Pharmaceutical companies in particular should factor in the time required for medical-legal review of the advertisement, which at many large pharma organisations can take two to four weeks on its own — meaning that the effective creative briefing deadline is closer to eight weeks before the issue print date. At SmartAds, we build a reverse timeline for every medical journal advertising India campaign we manage, working backward from the ad material submission deadline to identify when the brief needs to go to the creative team, when the first draft needs to be in medical-legal review, and when the final approved artwork needs to be dispatched to Jaypee Brothers.

There is also a seasonal dimension to IJIFM advertising that is worth thinking about strategically. The Indian medical conference calendar for reproductive medicine tends to cluster around certain months — the annual conferences of the Indian Fertility Society and FOGSI, for example, generate heightened clinical engagement with the specialty in the weeks before and after the event. Aligning an IJIFM print advertisement with the issue that lands closest to a major conference in the reproductive medicine calendar amplifies the brand's presence during a period when specialists are actively engaged with the latest developments in the field; this is a simple planning insight, but it is one that a surprising number of advertisers overlook when they treat journal advertising as a standalone channel rather than part of an integrated media plan.

What Are the Key Journal Metrics Advertisers Should Know About IJIFM?

The SJR impact factor IJIFM and associated metrics are questions that come up in almost every media planning conversation we have around medical journal advertising, and they deserve a clear-eyed answer rather than the vague reassurances that some publishers offer. The SCImago Journal Rank (SJR) score for IJIFM reflects its positioning as a specialty journal in a relatively focused clinical area, which means its absolute SJR value will naturally be lower than broad-scope journals with larger citation pools — but that comparison is somewhat misleading for advertisers, because the h-index journal metrics and CiteScore infertility journal values tell a more nuanced story about the journal's influence within its specific academic community. Advertisers are not buying advertising in IJIFM because it has a higher impact factor than the New England Journal of Medicine; they are buying it because it reaches a specific clinical audience that no other Indian journal addresses with the same focus.

The indexing status of IJIFM is a legitimate consideration for advertisers who care about the credibility signal that journal placement sends to clinician readers. The journal is indexed in several academic databases, and its digital preservation is handled through PORTICO, which is a recognised digital preservation service used by major academic publishers globally; the Sherpa Romeo self-archiving policy for IJIFM is also publicly available, which speaks to the journal's compliance with open access and archiving standards that are increasingly important in the academic publishing ecosystem. Whether IJIFM is indexed in Scopus or PubMed is a question that prospective advertisers ask frequently — and it is worth checking the current indexing status directly with Jaypee Brothers, as indexing decisions are reviewed periodically and the status may have changed since any secondary source was last updated.

Here is where it gets interesting from an advertiser's perspective: the open access journal model that IJIFM operates under, using the Creative Commons CC-BY-NC open access license, means that published articles are freely accessible online without a subscription barrier. This has a direct implication for digital advertisement reach — articles are shared, downloaded, and accessed by readers who are not formal subscribers, which expands the effective audience for digital banner advertisements placed on the journal's online platforms. The combination of PORTICO archiving, Sherpa Romeo compliance, and open access distribution through platforms like ScienceOpen and Researchgate means that IJIFM content — and the advertising placed around it — has a longer digital shelf life than a purely print or paywalled journal would provide.

Is Advertising in Indian Peer-Reviewed Medical Journals Worth the Investment?

The journal advertising ROI India question is one we get asked constantly, and our honest answer is that it depends entirely on what you are measuring and against what alternative. For a pharmaceutical company launching a new fertility drug or an IVF consumables brand entering the Indian market, the question is not whether IJIFM advertising generates the kind of reach numbers that a television campaign would — it obviously does not, and it is not designed to. The question is whether it reaches the right 2,000 or 5,000 specialists who will prescribe, recommend, or procure the product, and whether the cost of reaching those specialists through a peer-reviewed journal is competitive with the alternatives. When we run the numbers for clients, the medical magazine ad rates India for a full-page colour insertion in IJIFM work out to a CPM that is, in the ballpark of what you would pay for a highly targeted LinkedIn campaign aimed at healthcare professionals — but with the added credibility of a peer-reviewed editorial environment, which no digital platform can replicate.

We ran a detailed ROI analysis for a reproductive health supplement brand — a client based in Mumbai that was targeting gynaecologists and IVF specialists across Maharashtra and Karnataka. They had been allocating their entire specialist-facing budget to medical representative visits and conference sponsorships, with no journal advertising component at all. Over an 18-month period during which we introduced a two-journal strategy combining IJIFM with a regional obstetrics gynaecology journal, the brand's aided awareness among target specialists in those two states improved by a margin that their own market research team described as statistically significant — and the cost per incremental awareness point was considerably lower than what their conference sponsorships were delivering. To be fair, journal advertising works best as part of a multi-channel approach rather than as a standalone medium; the brands that get the most from IJIFM magazine advertising are the ones that combine it with conference presence, digital outreach, and field force activity rather than treating it as a replacement for any of those channels.

The KOL key opinion leader reproductive health dimension of medical journal advertising ROI is also worth acknowledging explicitly. Senior reproductive endocrinologists and fetomaternal medicine specialists who publish in journals like IJIFM are, by definition, the same people who influence prescribing patterns across their hospital networks and training programs. When a brand's advertisement appears in a journal that these KOLs read and contribute to, the association carries a credibility signal that is qualitatively different from what a digital banner or a conference booth delivers; it is a signal that the brand is serious about the clinical community, not just about selling product. This is a softer ROI dimension that is genuinely difficult to quantify but consistently reported by our clients as meaningful in their conversations with specialist prescribers.

What Are the Best Practices for Creating Compliant Pharmaceutical Ads in IJIFM?

Getting the creative right for a peer-reviewed infertility journal advertisement is a different discipline from consumer advertising or even general medical magazine creative, and the compliance dimension is only part of the challenge. The drug advertisement generic name requirement means that the INN or generic name must appear prominently — typically in the same font size or at least two-thirds the size of the brand name — which constrains the visual hierarchy of the advertisement in ways that consumer-facing creative does not have to manage. The marketing authorization summary product characteristics reference must be included, either as a condensed prescribing information panel or as a clear direction to the full document, which takes up space that a consumer advertiser would use for imagery or messaging.

The creative approach that we have found most effective in IJIFM and similar peer-reviewed journals is one that leads with a clinical insight rather than a brand claim — something that the specialist reader finds genuinely interesting or useful before they even register that they are reading an advertisement. A reproductive endocrinologist who picks up IJIFM is in a clinical mindset; an advertisement that opens with a relevant data point about treatment outcomes or a reference to a recently published trial finding will hold their attention far longer than one that leads with a brand logo and a tagline. This is not a novel insight in pharmaceutical marketing, but it is one that is consistently underweighted when creative briefs are written by teams more accustomed to consumer advertising. The commercially sponsored advertisement label must be clearly displayed, which is a transparency requirement that actually works in the advertiser's favour when the creative is strong — it signals that the brand is confident enough in its message to present it openly in an editorial environment.

For medtech advertising India companies, the compliance landscape is somewhat different from pharmaceutical advertising but no less important; medical device advertisements in IJIFM must accurately represent the device's approved indications and must not make comparative efficacy claims without supporting clinical evidence. At SmartAds, our standard process for any medtech client advertising in a peer-reviewed journal includes a pre-submission review against both the publisher's stated journal advertising policy and the relevant CDSCO device advertising guidelines — a step that adds a week to the timeline but has, without exception, saved our clients from costly revisions or rejections.

FAQ: Advertising in the International Journal of Infertility & Fetal Medicine

Q: How do I place an advertisement in the International Journal of Infertility & Fetal Medicine (IJIFM)?

The process for placing an advertisement in IJIFM begins with contacting Mr. Sanjeev Kumar at Jaypee Brothers Medical Publishers directly — his email is sanjeev.kumar@jaypeebrothers.com, and this is the correct point of contact for all advertising enquiries including rate card requests, format specifications, and booking confirmations. Once the format and issue have been agreed upon, a purchase order payment advertisement arrangement is typically made in advance of publication, and the ad material submission deadline of four weeks prior to the print date must be met with final approved artwork in the specified format. For brands working through an agency like SmartAds, the booking process can be managed entirely on the client's behalf, including rate negotiation for multi-issue commitments and coordination of artwork delivery to the publisher.

Q: What types of advertisements does IJIFM accept in print and digital formats?

In print, IJIFM accepts full-page colour and black-and-white advertisements, half-page insertions, back cover and inside cover premium positions, centre-spread placements, and bound-in inserts such as loose inserts and product monograph cards. Digital advertisement options are available through the Jaypee Journals online platform and JaypeeDigital, where banner advertisements can be placed alongside full-text article access; because IJIFM operates as an open access journal under the CC-BY-NC open access license, digital ad placements benefit from broader reader access than a paywalled journal would provide. The specific dimensions and file specifications for both print and digital formats should be confirmed with Mr. Sanjeev Kumar at the time of booking, as technical requirements are updated periodically.

Q: What is the lead time required to submit ad material before the IJIFM print date?

The standard ad material submission deadline for IJIFM is four weeks prior to the print date of the relevant issue, which is the minimum lead time required for the publisher to process and place the advertisement. In practice, pharmaceutical and medtech advertisers should plan for a significantly longer effective lead time — somewhere between eight and twelve weeks from creative briefing to final artwork delivery — to accommodate internal medical-legal review, regulatory compliance checking, and any revisions required by the IJIFM editorial team. Missing the four weeks prior print date deadline means waiting for the next issue in the triannual publication schedule, which is a three-to-four-month delay; early planning is not optional in this context, it is the only way to ensure placement in the desired issue.

Q: Who should I contact to book an advertisement in IJIFM?

Mr. Sanjeev Kumar at Jaypee Brothers Medical Publishers is the designated advertising contact for IJIFM, reachable at sanjeev.kumar@jaypeebrothers.com. Jaypee Brothers' offices are located at Ansari Road, Daryaganj, New Delhi – 110 002, which is the Daryaganj publisher address that has been the home of this health science publishing India institution for decades. For agencies managing multiple journal placements across the Jaypee Brothers portfolio — which includes IJIFM, DSJUOG, JSAFOG, and several other specialty journals — a single point of contact at the publisher's advertising department can manage all bookings, which simplifies the process considerably.

Q: What is the advertising policy of IJIFM regarding pharmaceutical and product ads?

IJIFM's journal advertising policy requires that all pharmaceutical advertisements comply with Indian drug advertising regulations, including the prominent display of the drug advertisement generic name, inclusion of prescribing information or a reference to the marketing authorization summary product characteristics, and clear labelling of the content as a commercially sponsored advertisement. The editorial independence of the journal is maintained strictly — advertising spend does not influence editorial content, and advertisers should not expect or request any form of editorial coverage in exchange for advertising placement. Product advertisements for medical devices and diagnostics must accurately represent approved indications and must not make unsubstantiated comparative efficacy claims; healthcare advertising compliance India requirements apply in full, and the publisher reserves the right to reject any advertisement that does not meet these standards.

Q: How much does it cost to advertise in IJIFM and what are the payment terms?

The medical magazine ad rates India for IJIFM vary by format, position, and colour specification, and the full rate card is available directly from Mr. Sanjeev Kumar at Jaypee Brothers. Based on our experience with Jaypee Brothers journal advertising, full-page colour insertions in specialty medical journals of this type are typically priced in the range that most specialty pharma marketing budgets would classify as a single-conference-sponsorship equivalent — somewhere between a few tens of thousands and a few lakhs of rupees depending on position and colour, with premium positions such as back cover and inside front cover carrying a meaningful premium over run-of-journal placements. Payment terms follow the standard purchase order payment advertisement model used across Indian medical publishing, with payment typically required in advance of publication; multi-issue bookings may attract negotiated rates, which is always worth discussing at the time of booking.

Q: What are IJIFM's journal metrics — impact factor, SJR, h-index, and CiteScore?

The SJR impact factor IJIFM and associated h-index journal metrics and CiteScore infertility journal values are available through the SCImago Journal Rank database and other academic indexing platforms; the most current values should be verified directly through these sources, as metrics are updated annually and any figure cited in a secondary source may be out of date. What is more important for advertisers to understand is that IJIFM's metrics reflect its positioning as a focused specialty journal in reproductive medicine and fetomaternal medicine — a niche that commands academic respect within its clinical community even if its absolute citation numbers are smaller than broad-scope general medical journals. The journal's digital preservation through PORTICO and its Sherpa Romeo self-archiving policy are indicators of its commitment to academic standards, which is the credibility context that makes advertising in a peer-reviewed journal meaningfully different from advertising in a trade publication.

Q: Who reads IJIFM — what is the target audience for advertisers?

The primary readership of IJIFM consists of reproductive endocrinologists, IVF specialists, embryologists, andrologists, fetomaternal medicine consultants, and senior obstetricians and gynaecologists with a subspecialty interest in infertility and fetal medicine. The gynaecologist readership India that IJIFM reaches is concentrated in tertiary care centres, private IVF clinics, and academic medical institutions, which are precisely the settings where prescribing and procurement decisions for fertility drugs, ART consumables, diagnostic equipment, and surgical devices are made. The secondary audience includes postgraduate students in obstetrics and gynaecology, research fellows in reproductive medicine, and hospital procurement officers — a readership layer that is particularly valuable for brands building long-term specialist relationships rather than purely transactional awareness.

Q: Can non-pharmaceutical or general/blog brands advertise in IJIFM?

Yes — IJIFM does accept blog general advertising India and non-pharmaceutical brand advertising, provided the content is relevant to the clinical readership and complies with the journal's advertising standards. Brands in medical education, healthcare technology, laboratory equipment, fertility supplements, and health information services are all potential advertisers in this category; the key requirement is that the advertisement content is appropriate for a specialist clinical audience and does not make unsubstantiated health claims. For general health brands seeking to build awareness among clinicians in the reproductive health space, IJIFM represents a relatively accessible entry point into medical journal advertising India compared to the more complex compliance requirements that pharmaceutical advertising entails.

Q: What types of advertisements will IJIFM reject under its editorial policy?

Advertisements that make unsubstantiated clinical efficacy claims, promote prescription drugs for off-label indications, use comparative efficacy data without peer-reviewed citation support, or fail to include required prescribing information will be rejected by the IJIFM editorial team. Advertisements that do not clearly identify themselves as commercially sponsored content, or that appear designed to mimic editorial content in a way that could mislead readers, will also be rejected; this is a standard requirement across peer-reviewed medical journals and is consistent with both CDSCO guidelines and the International Committee of Medical Journal Editors (ICMJE) advertising standards. In our experience, the most common grounds for rejection are inadequate prescribing information panels and unsubstantiated comparative claims — both of which are avoidable with proper pre-submission compliance review.

Q: How does advertising in IJIFM compare to advertising in other Indian reproductive medicine journals?

IJIFM occupies a unique position in the Indian medical journal landscape because it is the only peer-reviewed journal with a dedicated dual focus on infertility and fetal medicine, which makes it the most precisely targeted advertising vehicle available for brands in the assisted reproduction and fetomaternal medicine space. Compared to broader obstetrics gynaecology journals like IJOGR or the FOGSI publication advertising vehicle JSAFOG, IJIFM delivers a more concentrated specialist audience at the cost of lower absolute circulation numbers — a trade-off that typically favours IJIFM for brands with a specific IVF advertising or ART journal India focus. For brands with broader clinical targets that span general gynaecology, a multi-journal strategy that includes IJIFM alongside a higher-circulation obstetrics journal will generally deliver better coverage than either publication alone.

Q: Is IJIFM indexed in Scopus or PubMed — and why does it matter for advertisers?

The indexing status of IJIFM in databases like Scopus and PubMed is a question that should be verified directly with Jaypee Brothers or through the relevant database's official journal list, as indexing decisions are reviewed and updated periodically. From an advertiser's perspective, Scopus and PubMed indexing matters because it signals to the clinical readership that the journal meets rigorous peer-review and publication standards, which in turn affects how seriously specialists regard the journal — and, by association, the brands that advertise in it. A journal that is indexed in major academic databases is one that KOL key opinion leader reproductive health figures actively read, cite, and recommend to their trainees; advertising in such a journal carries a credibility endorsement that is genuinely valuable for pharmaceutical and medtech brands trying to establish scientific credibility in a specialist clinical community.

**Q: Does IJIFM offer digital or online advertising options